Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Authors
Discussion
Loading...
Member takes
Overview
Observational analysis shows that vutrisiran improves cardiac biomarkers in patients with transthyretin amyloidosis, suggesting potential for reduced mortality.
Key Points
- Vutrisiran treatment resulted in significantly lower levels of NT-proBNP and troponin I compared to placebo after 30 months.
- Increases in NT-proBNP and decreases in troponin I were linked to higher and lower risks of all-cause mortality, respectively.
- The double-blind, placebo-controlled HELIOS-B study involved 655 patients with transthyretin amyloidosis and assessed various cardiac outcomes.
- Biomarkers NT-proBNP and troponin I are crucial in predicting outcomes, highlighting the need for timely treatment initiation.
Cite This Study
Maurer et al. (2025) studied this question.